Companies that own Healios K.K.
JPMorgan Asset Management (Japan) Ltd.
2,607,900
5.3%
2,607,900
0.32%
02/15/2018
Baillie Gifford & Co.
1,345,500
2.73%
70,600
0.01%
04/30/2018
Matthews International Capital Management LLC
380,100
0.77%
0
0.02%
06/29/2018
Asset Management One Co., Ltd.
306,700
0.62%
-13,000
0%
01/15/2018
AXA Investment Managers UK Ltd.
204,200
0.42%
37,700
0.01%
02/15/2018
Nomura Asset Management Co., Ltd.
162,400
0.33%
1,800
0%
11/30/2017
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
128,401
0.26%
88,501
0%
02/26/2018
Simplex Asset Management Co., Ltd.
117,000
0.24%
67,000
0.15%
09/20/2016
Indus Capital Partners LLC
93,800
0.19%
93,800
0.09%
09/30/2017
GO ETF Solutions LLP
89,800
0.18%
89,800
0.07%
02/28/2018
| Address |
World Trade Center Building, 15/F
Tokyo Tokyo 105
Japan
|
|
Employees
|
- |
| Website |
http://www.healios.co.jp |
| Updated |
07/08/2019 |
| Healios KK engages in the development and sale of ophthalmological surgery adjuvants. It aims to commercialize pharmaceutical hiPSC derived retinal pigment epithelium (RPE) cell transplantation for the treatment of age-related macular degeneration. The firm develops therapies for the regeneration of retinal function and to improve visual function in those affected with retinal degenerative diseases. |
